San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

Join Lee Rennick from the CIO100 with Bob McCowan, SVP & CIO, Regeneron as he discusses the award-winning Centralized Data ...

Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Regeneron Pharmaceuticals Inc. closed 44.20% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

The pharmaceuticals company recruits a cohort of data interns through the international IT consulting firm, challenging ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

The six were among 40 finalists nationwide in the Regeneron Science Talent Search, the country's most prestigious science ...